American Healthcare REIT to Participate at BofA Securities 2026 Global Real Estate Conference

American Healthcare REIT said Chairman and CEO Jeff Hanson, President and COO Gabe Willhite, and VP of Investor Relations & Finance Alan Peterson will participate in a BofA Securities Global Real Estate Conference roundtable on September 15, 2026, from 12:45 p.m. to 1:20 p.m. ET. The announcement provides an investor-engagement update but contains no financial results, guidance, or material corporate developments.

Analysis

This is a low-information event rather than a fundamental catalyst; no position should be initiated solely on management’s conference appearance. The relevant signal is whether management uses the forum to narrow the market’s uncertainty around senior-housing occupancy, same-store NOI growth, external-acquisition underwriting, and the cost of financing incremental investments. AHR’s valuation remains especially sensitive to the spread between private-market healthcare real-estate cap rates and its own cost of equity/debt.

Near term, monitor for any change in language on labor expense, rent coverage at skilled-nursing tenants, or disposition activity. A credible path to sustained occupancy and NOI acceleration could support multiple expansion over the next 1-3 months, but generic commentary is unlikely to overcome REIT-sector rate sensitivity. Conversely, disclosure of acquisition ambitions without identified funding sources would raise dilution and leverage concerns, particularly if long-duration Treasury yields move higher.

The non-obvious read-through is to healthcare REIT peers: stronger senior-housing fundamentals would be more meaningful for WELL and VTR, whose scale and operating-platform exposure provide greater upside to occupancy-driven margin recovery. AHR may offer higher beta to improving private-market transaction conditions, but it also has less room for capital-allocation mistakes given a shorter public-market record and potentially higher perceived financing risk.

Key Decisions for Investors

• No new directional AHR trade before the September 15 presentation; treat it as an information-gathering event, not a standalone catalyst.
• Set an alert to review AHR if management quantifies same-store NOI/occupancy acceleration or commits to asset sales that reduce leverage without impairing FFO; a post-event pullback with improved guidance would be a more attractive entry than pre-positioning.
• For a healthcare-real-estate recovery view over 6-18 months, prefer long WELL versus AHR: WELL offers greater liquidity and cleaner exposure to senior-housing operating leverage. Reassess if 10-year Treasury yields rise materially or senior-housing occupancy stops improving.
• If AHR outlines externally funded acquisitions without clear asset-sale proceeds or retained-cash-flow coverage, consider AHR underweight versus XLRE for 1-3 months; falsify the view if management demonstrates accretion after financing and leverage declines.